Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06738303 · ClinicalTrials.gov registry record · Phase 2

Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer

A Phase 2 study of Metastatic Castration-Resistant Prostate Cancer and Metastatic Prostate Cancer, sponsored by Case Comprehensive Cancer Center.

Recruiting
Registry status
Phase 2
Development phase
44
Enrollment target
1
Study location

NCT06738303 is a Phase 2 study of Metastatic Castration-Resistant Prostate Cancer and Metastatic Prostate Cancer that is actively recruiting participants, run by Case Comprehensive Cancer Center. The registered enrollment target is 44 participants, below the 197-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06738303, a Phase 2 study of Metastatic Castration-Resistant Prostate Cancer and Metastatic Prostate Cancer, is actively recruiting participants, sponsored by Case Comprehensive Cancer Center.

RECRUITING
Registry status
Phase 2
Development phase
44 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to find out what treatment works best for participants with metastatic prostate cancer that are not responding to hormone treatment and docetaxel and are also Prostate-specific membrane antigen(PSMA) positive.

Conditions Studied

Metastatic Castration-Resistant Prostate Cancer Metastatic Prostate Cancer

Interventions

  • DRUG Cabazitaxel and carboplatin
  • DRUG Lu-PSMA-617

Study Locations (1)

Ohio

  • Case Comprehensive Cancer Center, University Hospitals Cleveland Medical Center Seidman Cancer Center, Cleveland Clinic Taussig Cancer Center - Cleveland

Trial Details

FieldValue
Enrollment Target 44 participants
Start Date 2025-07-14
Est. Completion 2026-12
Phase Phase 2

Sponsor

Case Comprehensive Cancer Center

407 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06738303

The ClinicalTrials.gov registry entry for NCT06738303 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 197-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (78% lower). The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Metastatic Castration-Resistant Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Cabazitaxel and carboplatin is the first listed.

NCT06738303 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT06738303 about?

NCT06738303 is a clinical study titled "Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer". The purpose of this study is to find out what treatment works best for participants with metastatic prostate cancer that are not responding to hormone treatment and docetaxel and are also Prostate-specific membrane antigen(PSMA) positive.

What is the current status of trial NCT06738303?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2025-07-14. Estimated completion is 2026-12.

What conditions does trial NCT06738303 study?

This clinical trial studies the following conditions: Metastatic Castration-Resistant Prostate Cancer, Metastatic Prostate Cancer.

What interventions are being tested in trial NCT06738303?

The interventions under investigation include: Cabazitaxel and carboplatin (DRUG), Lu-PSMA-617 (DRUG).

Who is sponsoring clinical trial NCT06738303?

This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06738303 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Castration-Resistant Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Castration-Resistant Prostate Cancer

All registered trials for this condition

Metastatic Prostate Cancer

All registered trials for this condition

Ohio

All trials with a study site in Ohio

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.